My conclusion is that the outcome was more likely the result of closer attention and better follow-up. The trial design was not adequate to answer the question that was posed.
MANDEEP R. MEHRA, M.B.B.S., is head of the division of cardiology at the University of Maryland in Baltimore. He has received consulting fees or honoraria from Medtronic, St. Jude/Boston Scientific, Solvay, and Geron.